This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. 

We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

Editor-in-Chief:
Ruben A. Mesa (UT Health San Antonio Cancer Center, San Antonio, Texas, USA)
Editorial Board:
Frederick R. Appelbaum (Fred Hutchinson Cancer Research Center, Seattle, Washington, USA) 
Michele Baccarani (University of Bologna, Bologna, Italy)
John C. Byrd (Ohio State University, Columbus, Ohio, USA)
Myron S. Czuczman (Roswell Park Cancer Institute, Buffalo, New York, USA)
David Gomez-Almaguer (Hospital Universitario UANL, Monterrey, Mexico)
Nelson Hamerschlack (Hospital Israelita Albert Einstein, Sao Paulo, Brazil)
Jean-Luc Harousseau (University Hospital Hotel Dieu, Nantes, France)
Claire Harrison (Guy's and St. Thomas' NHS Foundation Trust, London, England, United Kingdom)
Armand Keating (Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Ontario, Canada)
Alan F. List (H. Lee Moffitt Cancer Center, Tampa, Florida, USA)
Jesús San Miguel (Hospital Universitario de Salamanca, Salamanca, Spain)
Emili Montserrat (University of Barcelona, Barcelona, Spain)
Carolina Pavlovsky (Angelica Ocampo Hospitalization and Clinical Research Center, Buenos Aires, Argentina)
Ching-Hon Pui (St. Jude Children’s Research Hospital, Memphis, Tennessee, USA)
John F. Seymour (Peter MacCallum Cancer Centre, Melbourne, Australia)
Koen Van Besien (University of Chicago, Chicago, Illinois, USA)
Sections and Section Editors:
Stem Cell Transplantation
Richard Maziarz (Oregon Health & Science University, Portland, Oregon, USA)
T-Cell and Other Lymphoproliferative Malignancies
Jasmine Zain (City of Hope Medical Center, Duarte, California, USA)
Multiple Myeloma 
Prashant Kapoor (Mayo Clinic, Rochester, Minnesota, USA)
Chronic Lymphocytic Leukemias
Nitin Jain (University of Texas MD Anderson Cancer Center, Houston, Texas, USA)
Acute Lymphocytic Leukemias 
Karen Ballen (University of Virginia Health System, Charlottesville, Virginia, USA)
Michael Keng (University of Virginia Health System, Charlottesville, Virginia, USA)
Health Economics
Nandita Khera (Mayo Clinic, Phoenix, Arizona, USA)
Myeloproliferative Neoplasms
Brady Stein (Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA)
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma
Jennifer Amengual (Columbia University, New York, New York, USA)
CART and Immunotherapy
Marco Ruella (University of Pennsylvania, Philadelphia, Pennsylvania, USA)
Patrick Hanley (Children's National Health System, Washington, DC, USA)
Molecular Testing and Diagnostics
Joseph Khoury (University of Texas MD Anderson Cancer Center, Houston, Texas, USA)
Myelodysplastic Syndromes
Michael Savona (Vanderbilt University School of Medicine, Nashville, Tennessee, USA)
Acute Myeloid Leukemias
Harry Erba (Duke University School of Medicine, Durham, North Carolina, USA)
Chronic Myeloid Leukemias
Michael J. Mauro (Memorial Sloan Kettering Cancer Center, New York, NY, USA)
Guiseppe Saglio (University of Turin, Turin, Italy)
Social Media Impact of Hematologic Malignancies
Naveen Pemmaraju (MD Anderson Cancer Center, Houston, Texas, USA)